<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Antidepressants, SSRI: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int232-antidepressants-ssri.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int232-antidepressants-ssri.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="bnf_int232-antidepressants-ssri.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a> &gt; <a href="bnf_int229-antidepressants.htm">Antidepressants</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int231-reboxetine.htm" title="Previous: Reboxetine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int964-escitalopram.htm" title="Next: Escitalopram">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1>Antidepressants, SSRI</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p><strong>Antidepressants, SSRI</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>sedative effects possibly increased when </span><span>SSRIs</span> <span>given with</span> <span>alcohol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span></span> <span>SSRIs</span> <span>increase plasma concentration of some</span> <span>tricyclics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int276-antiepileptics.htm">Antiepileptics</a></td><td class="cAI"><p><span></span> <span>SSRIs</span> <span>antagonise anticonvulsant effect of</span> <span>antiepileptics</span> <span>(convulsive threshold lowered)</span></p></td><td></td></tr><tr><td><a href="bnf_int361-aspirin.htm">Aspirin</a></td><td class="cAI"><p><span>increased risk of bleeding when </span><span>SSRIs</span> <span>given with</span> <span>aspirin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int220-coumarins.htm">Coumarins</a></td><td class="cAI"><p><span></span> <span>SSRIs</span> <span>possibly enhance anticoagulant effect of</span> <span>coumarins</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Change in patient's clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</p></div></td></tr><tr><td><a href="bnf_int317-cyproheptadine.htm">Cyproheptadine</a></td><td><p><span>antidepressant effect of </span><span>SSRIs</span> <span>possibly antagonised by</span> <span>cyproheptadine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1120-dabigatran-etexilate.htm">Dabigatran Etexilate</a></td><td class="cAI"><p><span>possible increased risk of bleeding when </span><span>SSRIs</span> <span>given with</span> <span>dabigatran etexilate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td><p><span>possible increased serotonergic effects when </span><span>SSRIs</span> <span>given with</span> <span>duloxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int372-lithium.htm">Lithium</a></td><td class="cAI"><p><span>Increased risk of CNS effects when </span><span>SSRIs</span> <span>given with</span> <span>lithium</span> <span>(<span>lithium</span> toxicity reported)</span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>CNS effects of </span><span>SSRIs</span> <span>increased by</span> <span>MAOIs</span> <span>(risk of serious toxicity)</span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int718-methylphenidate.htm">Methylphenidate</a></td><td><p><span>metabolism of </span><span>SSRIs</span> <span>possibly inhibited by</span> <span>methylphenidate</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1224-methylthioninium.htm">Methylthioninium</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span><span>SSRIs</span> <span>given with</span> <span>methylthioninium</span><span>—avoid concomitant use (if avoidance not possible, use lowest possible dose of <span>methylthioninium</span> and observe patient for up to 4 hours after administration)</span></p></td><td></td></tr><tr><td><a href="bnf_int613-metoclopramide.htm">Metoclopramide</a></td><td><p><span>CNS toxicity reported when </span><span>SSRIs</span> <span>given with</span> <span>metoclopramide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int60-nsaids.htm">NSAIDs</a></td><td class="cAI"><p><span>increased risk of bleeding when </span><span>SSRIs</span> <span>given with</span> <span>NSAIDs</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>See also </em>Aspirin. Interactions do not generally apply to topical NSAIDs
</p></div></td></tr><tr><td><a href="bnf_int573-naratriptan.htm">Naratriptan</a></td><td><p><span>possible increased serotonergic effects when </span><span>SSRIs</span> <span>given with</span> <span>naratriptan</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int369-pimozide.htm">Pimozide</a></td><td class="cAI"><p><span></span> <span>SSRIs</span> <span>possibly increase plasma concentration of</span> <span>pimozide</span> <span>(increased risk of ventricular arrhythmias—avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>SSRIs</span> <span>given with</span> <span>rasagiline</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td class="cAI"><p><span>plasma concentration of </span><span>SSRIs</span> <span>possibly increased by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int905-st-johns-wort.htm">St John's Wort</a></td><td class="cAI"><p><span>increased serotonergic effects when </span><span>SSRIs</span> <span>given with</span> <span>St John's wort</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int106-tramadol.htm">Tramadol</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>SSRIs</span> <span>given with</span> <span>tramadol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int263-tryptophan.htm">Tryptophan</a></td><td class="cAI"><p><span>agitation and nausea may occur when </span><span>SSRIs</span> <span>given with</span> <span>tryptophan</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Antidepressants, SSRI</strong> belongs to <strong>Antidepressants</strong> and will have the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int937-artemether-with-lumefantrine.htm">Artemether with Lumefantrine</a></td><td class="cAI"><p><span>avoidance of </span><span>antidepressants</span> <span>advised by manufacturer of</span> <span>artemether with lumefantrine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td><p><span>possible increased risk of convulsions when </span><span>antidepressants</span> <span>given with</span> <span>atomoxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1237-piperaquine-with-artenimol.htm">Piperaquine with Artenimol</a></td><td class="cAI"><p><span>avoidance of </span><span>antidepressants</span> <span>advised by manufacturer of</span> <span>piperaquine with artenimol</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Piperaquine has a long half-life; there is a potential for drug interactions to occur for up to 3 months after treatment has been stopped</p></div></td></tr></tbody></table><p><strong>Escitalopram</strong> belongs to <strong>Antidepressants, SSRI</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span><span>escitalopram</span> <span>increased by</span> <span>cimetidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>escitalopram</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span><span>, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>escitalopram</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int451-metoprolol.htm">Metoprolol</a></td><td><p><span></span> <span>escitalopram</span> <span>increases plasma concentration of</span> <span>metoprolol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>escitalopram</span> <span>given with</span> <span>moclobemide</span><span>, preferably avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int752-omeprazole.htm">Omeprazole</a></td><td><p><span>plasma concentration of </span><span>escitalopram</span> <span>increased by</span> <span>omeprazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td><p><span>avoidance of </span><span>escitalopram</span> <span>advised by manufacturer of</span> <span>selegiline</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>escitalopram</span> <span>given with</span> <span>sumatriptan</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Citalopram</strong> belongs to <strong>Antidepressants, SSRI</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int572-5ht-1-receptor-agonists.htm">5HT<sub>1</sub>-receptor Agonists</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>citalopram</span> <span>given with</span> <span>5HT<sub>1</sub> agonists</span> <span>(manufacturer of <span>citalopram</span> advises avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td><p><span>plasma concentration of </span><span>citalopram</span> <span>possibly increased by</span> <span>bupropion</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span><span>citalopram</span> <span>increased by</span> <span>cimetidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td><p><span></span> <span>citalopram</span> <span>possibly increases plasma concentration of</span> <span>clozapine</span> <span>(increased risk of toxicity)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>citalopram</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span><span>, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>citalopram</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int451-metoprolol.htm">Metoprolol</a></td><td><p><span></span> <span>citalopram</span> <span>increases plasma concentration of</span> <span>metoprolol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span><span>citalopram</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span></p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td><p><span>avoidance of </span><span>citalopram</span> <span>advised by manufacturer of</span> <span>selegiline</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>citalopram</span> <span>given with</span> <span>sumatriptan</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int946-telithromycin.htm">Telithromycin</a></td><td class="cAI"><p><span>possible increased risk of ventricular arrhythmias when </span><span>citalopram</span> <span>given with</span> <span>telithromycin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td><p><span>possible increased risk of bleeding when </span><span>citalopram</span> <span>given with</span> <span>ticagrelor</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Fluoxetine</strong> belongs to <strong>Antidepressants, SSRI</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int406-alprazolam.htm">Alprazolam</a></td><td><p><span></span> <span>fluoxetine</span> <span>increases plasma concentration of</span> <span>alprazolam</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>possibly inhibits metabolism of</span> <span>aripiprazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td><p><span></span> <span>fluoxetine</span> <span>possibly inhibits metabolism of</span> <span>atomoxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>increases plasma concentration of</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>increases plasma concentration of</span> <span>clozapine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>avoidance of </span><span>fluoxetine</span> <span>advised by manufacturer of</span> <span>droperidol</span> <span>(risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int120-flecainide.htm">Flecainide</a></td><td><p><span></span> <span>fluoxetine</span> <span>increases plasma concentration of</span> <span>flecainide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>increases plasma concentration of</span> <span>haloperidol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span><span>, also <span>MAOIs</span> should not be started until at least 5 weeks after stopping <span>fluoxetine</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>fluoxetine</span> <span>possibly increases plasma concentration of</span> <span>methadone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int823-mirtazapine.htm">Mirtazapine</a></td><td><p><span>possible increased serotonergic effects when </span><span>fluoxetine</span> <span>given with</span> <span>mirtazapine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span><span>fluoxetine</span> <span>do not start</span> <span>moclobemide</span> <span>for 5 weeks</span></p></td><td></td></tr><tr><td><a href="bnf_int475-nifedipine.htm">Nifedipine</a></td><td><p><span></span> <span>fluoxetine</span> <span>possibly inhibits metabolism of</span> <span>nifedipine</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>increases plasma concentration of</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int125-propafenone.htm">Propafenone</a></td><td><p><span></span> <span>fluoxetine</span> <span>possibly inhibits metabolism of</span> <span>propafenone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>should not be started until 2 weeks after stopping</span> <span>rasagiline</span><span>, also <span>rasagiline</span> should not be started until at least 5 weeks after stopping <span>fluoxetine</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int368-risperidone.htm">Risperidone</a></td><td><p><span></span> <span>fluoxetine</span> <span>increases plasma concentration of</span> <span>risperidone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span><span>fluoxetine</span> <span>given with</span> <span>selegiline</span> <span>(<span>selegiline</span> should not be started until 5 weeks after stopping <span>fluoxetine</span>, avoid <span>fluoxetine</span> for 2 weeks after stopping <span>selegiline</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>fluoxetine</span> <span>given with</span> <span>sumatriptan</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int581-tamoxifen.htm">Tamoxifen</a></td><td class="cAI"><p><span></span> <span>fluoxetine</span> <span>possibly inhibits metabolism of</span> <span>tamoxifen</span> <span>to active metabolite (avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int263-tryptophan.htm">Tryptophan</a></td><td><p><span>CNS toxicity reported when </span><span>fluoxetine</span> <span>given with</span> <span>tryptophan</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Fluvoxamine</strong> belongs to <strong>Antidepressants, SSRI</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1145-agomelatine.htm">Agomelatine</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>inhibits metabolism of</span> <span>agomelatine</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int1209-asenapine.htm">Asenapine</a></td><td><p><span></span> <span>fluvoxamine</span> <span>possibly increases plasma concentration of</span> <span>asenapine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int405-benzodiazepines.htm">Benzodiazepines</a></td><td><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of some</span> <span>benzodiazepines</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int277-carbamazepine.htm">Carbamazepine</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>carbamazepine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int865-clopidogrel.htm">Clopidogrel</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>possibly reduces antiplatelet effect of</span> <span>clopidogrel</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>clozapine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>avoidance of </span><span>fluvoxamine</span> <span>advised by manufacturer of</span> <span>droperidol</span> <span>(risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int1024-duloxetine.htm">Duloxetine</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>inhibits metabolism of</span> <span>duloxetine</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int965-frovatriptan.htm">Frovatriptan</a></td><td><p><span></span> <span>fluvoxamine</span> <span>inhibits the metabolism of</span> <span>frovatriptan</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int387-haloperidol.htm">Haloperidol</a></td><td><p><span></span> <span>fluvoxamine</span> <span>possibly increases plasma concentration of</span> <span>haloperidol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int753-lansoprazole.htm">Lansoprazole</a></td><td><p><span></span> <span>fluvoxamine</span> <span>possibly increases plasma concentration of</span> <span>lansoprazole</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span><span>, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>fluvoxamine</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int1114-melatonin.htm">Melatonin</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>melatonin</span><span>—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>fluvoxamine</span> <span>possibly increases plasma concentration of</span> <span>methadone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int823-mirtazapine.htm">Mirtazapine</a></td><td><p><span>possible increased serotonergic effects when </span><span>fluvoxamine</span> <span>given with</span> <span>mirtazapine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span><span>fluvoxamine</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span></p></td><td></td></tr><tr><td><a href="bnf_int366-olanzapine.htm">Olanzapine</a></td><td><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>olanzapine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int793-propranolol.htm">Propranolol</a></td><td><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>propranolol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>should not be started until 2 weeks after stopping</span> <span>rasagiline</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int231-reboxetine.htm">Reboxetine</a></td><td class="cAI"><p><span>avoidance of </span><span>fluvoxamine</span> <span>advised by manufacturer of</span> <span>reboxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1190-roflumilast.htm">Roflumilast</a></td><td><p><span></span> <span>fluvoxamine</span> <span>inhibits the metabolism of</span> <span>roflumilast</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int888-ropivacaine.htm">Ropivacaine</a></td><td><p><span></span> <span>fluvoxamine</span> <span>inhibits metabolism of</span> <span>ropivacaine</span><span>—avoid prolonged administration of <span>ropivacaine</span></span></p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span><span>fluvoxamine</span> <span>given with</span> <span>selegiline</span> <span>(<span>selegiline</span> should not be started until 1 week after stopping <span>fluvoxamine</span>, avoid <span>fluvoxamine</span> for 2 weeks after stopping <span>selegiline</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>fluvoxamine</span> <span>given with</span> <span>sumatriptan</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int734-theophylline.htm">Theophylline</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>theophylline</span> <span>(concomitant use should usually be avoided, but where not possible halve <span>theophylline</span> dose and monitor plasma-<span>theophylline</span> concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int805-tizanidine.htm">Tizanidine</a></td><td class="cAI"><p><span></span> <span>fluvoxamine</span> <span>increases plasma concentration of</span> <span>tizanidine</span> <span>(increased risk of toxicity)—avoid concomitant use</span></p></td><td></td></tr><tr><td><a href="bnf_int575-zolmitriptan.htm">Zolmitriptan</a></td><td><p><span></span> <span>fluvoxamine</span> <span>possibly inhibits metabolism of</span> <span>zolmitriptan</span> <span>(reduce dose of <span>zolmitriptan</span>)</span></p></td><td></td></tr></tbody></table><p><strong>Paroxetine</strong> belongs to <strong>Antidepressants, SSRI</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int1011-aripiprazole.htm">Aripiprazole</a></td><td class="cAI"><p><span></span> <span>paroxetine</span> <span>possibly inhibits metabolism of</span> <span>aripiprazole</span> <span>(reduce dose of <span>aripiprazole</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int1209-asenapine.htm">Asenapine</a></td><td><p><span>plasma concentration of </span><span>paroxetine</span> <span>possibly increased by</span> <span>asenapine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1009-atomoxetine.htm">Atomoxetine</a></td><td><p><span></span> <span>paroxetine</span> <span>possibly inhibits metabolism of</span> <span>atomoxetine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span></span> <span>paroxetine</span> <span>increases plasma concentration of</span> <span>clozapine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int1076-darifenacin.htm">Darifenacin</a></td><td><p><span></span> <span>paroxetine</span> <span>increases plasma concentration of</span> <span>darifenacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td><p><span>plasma concentration of </span><span>paroxetine</span> <span>possibly reduced by</span> <span>darunavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int915-galantamine.htm">Galantamine</a></td><td><p><span></span> <span>paroxetine</span> <span>increases plasma concentration of</span> <span>galantamine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>paroxetine</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span><span>, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>paroxetine</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>paroxetine</span> <span>possibly increases plasma concentration of</span> <span>methadone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int451-metoprolol.htm">Metoprolol</a></td><td><p><span></span> <span>paroxetine</span> <span>possibly increases plasma concentration of</span> <span>metoprolol</span> <span>(enhanced effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span><span>paroxetine</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span></p></td><td></td></tr><tr><td><a href="bnf_int381-perphenazine.htm">Perphenazine</a></td><td><p><span></span> <span>paroxetine</span> <span>inhibits metabolism of</span> <span>perphenazine</span> <span>(reduce dose of <span>perphenazine</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int437-phenobarbital.htm">Phenobarbital</a></td><td><p><span>plasma concentration of </span><span>paroxetine</span> <span>reduced by</span> <span>phenobarbital</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span><span>paroxetine</span> <span>reduced by</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int354-procyclidine.htm">Procyclidine</a></td><td><p><span></span> <span>paroxetine</span> <span>increases plasma concentration of</span> <span>procyclidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int125-propafenone.htm">Propafenone</a></td><td><p><span></span> <span>paroxetine</span> <span>possibly inhibits metabolism of</span> <span>propafenone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1147-ranolazine.htm">Ranolazine</a></td><td><p><span></span> <span>paroxetine</span> <span>increases plasma concentration of</span> <span>ranolazine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int368-risperidone.htm">Risperidone</a></td><td><p><span></span> <span>paroxetine</span> <span>possibly increases plasma concentration of</span> <span>risperidone</span> <span>(increased risk of toxicity)</span></p></td><td></td></tr><tr><td><a href="bnf_int400-ritonavir.htm">Ritonavir</a></td><td><p><span>plasma concentration of </span><span>paroxetine</span> <span>possibly reduced by</span> <span>ritonavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span><span>paroxetine</span> <span>given with</span> <span>selegiline</span> <span>(<span>selegiline</span> should not be started until 2 weeks after stopping <span>paroxetine</span>, avoid <span>paroxetine</span> for 2 weeks after stopping <span>selegiline</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>paroxetine</span> <span>given with</span> <span>sumatriptan</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int581-tamoxifen.htm">Tamoxifen</a></td><td class="cAI"><p><span></span> <span>paroxetine</span> <span>possibly inhibits metabolism of</span> <span>tamoxifen</span> <span>to active metabolite (avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td><p><span>possible increased risk of bleeding when </span><span>paroxetine</span> <span>given with</span> <span>ticagrelor</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Sertraline</strong> belongs to <strong>Antidepressants, SSRI</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>plasma concentration of </span><span>sertraline</span> <span>increased by</span> <span>cimetidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int364-clozapine.htm">Clozapine</a></td><td class="cAI"><p><span></span> <span>sertraline</span> <span>increases plasma concentration of</span> <span>clozapine</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</p></div></td></tr><tr><td><a href="bnf_int1091-darunavir.htm">Darunavir</a></td><td><p><span>plasma concentration of </span><span>sertraline</span> <span>possibly reduced by</span> <span>darunavir</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1152-droperidol.htm">Droperidol</a></td><td class="cAI"><p><span>avoidance of </span><span>sertraline</span> <span>advised by manufacturer of</span> <span>droperidol</span> <span>(risk of ventricular arrhythmias)</span></p></td><td></td></tr><tr><td><a href="bnf_int829-grapefruit-juice.htm">Grapefruit Juice</a></td><td><p><span>plasma concentration of </span><span>sertraline</span> <span>possibly increased by</span> <span>grapefruit juice</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span></span> <span>sertraline</span> <span>should not be started until 2 weeks after stopping</span> <span>MAOIs</span><span>, also <span>MAOIs</span> should not be started until at least 1 week after stopping <span>sertraline</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int97-methadone.htm">Methadone</a></td><td><p><span></span> <span>sertraline</span> <span>possibly increases plasma concentration of</span> <span>methadone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>after stopping </span><span>sertraline</span> <span>do not start</span> <span>moclobemide</span> <span>for at least 1 week</span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>plasma concentration of </span><span>sertraline</span> <span>possibly reduced by</span> <span>phenytoin</span><span>, also plasma concentration of <span>phenytoin</span> possibly increased</span></p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span><span>sertraline</span> <span>given with</span> <span>selegiline</span> <span>(<span>selegiline</span> should not be started until 1 week after stopping <span>sertraline</span>, avoid <span>sertraline</span> for 2 weeks after stopping <span>selegiline</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int574-sumatriptan.htm">Sumatriptan</a></td><td><p><span>CNS toxicity reported when </span><span>sertraline</span> <span>given with</span> <span>sumatriptan</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1203-ticagrelor.htm">Ticagrelor</a></td><td><p><span>possible increased risk of bleeding when </span><span>sertraline</span> <span>given with</span> <span>ticagrelor</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int425-zolpidem.htm">Zolpidem</a></td><td><p><span>sedative effects possibly increased when </span><span>sertraline</span> <span>given with</span> <span>zolpidem</span> <span></span></p></td><td></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int964-escitalopram.htm" title="Escitalopram">Escitalopram</a></li><li><a href="bnf_int233-citalopram.htm" title="Citalopram">Citalopram</a></li><li><a href="bnf_int234-fluoxetine.htm" title="Fluoxetine">Fluoxetine</a></li><li><a href="bnf_int235-fluvoxamine.htm" title="Fluvoxamine">Fluvoxamine</a></li><li><a href="bnf_int236-paroxetine.htm" title="Paroxetine">Paroxetine</a></li><li><a href="bnf_int237-sertraline.htm" title="Sertraline">Sertraline</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int231-reboxetine.htm">Previous: Reboxetine</a> | <a class="top" href="bnf_int232-antidepressants-ssri.htm#">Top</a> | <a accesskey="]" href="bnf_int964-escitalopram.htm">Next: Escitalopram</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>